As China edges towards becoming the world’s largest pharma market, there has been a flurry of IPOs among its domestic manufacturers, says Asia correspondent A Nair
As Beijing ramps up funding and incentives for R&D, research firm Deloitte expects China’s life sciences and healthcare market to become the second largest in the world within a decade. Biotech output, meanwhile, is on course to reach US$630bn, 90% of which will come from biopharma.
Private equity and venture capital investment in pharma and biotech in China reached £596m ($953m) last year, up 31.6% from 2010. Investor appetite appears to remain steady in 2012, with £388m ($620m) committed to eight deals in the first six months of the year.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.